Once-Weekly Exenatide in Youth With Type 2 Diabetes | Zendy

William V. Tamborlane | Zendy; Raafat Bishai | Zendy; David H. Geller | Zendy; Naim Shehadeh | Zendy; Dalia AlAbdulrazzaq | Zendy; Evelina Mánica Vazquez | Zendy; Eva Karoly | Zendy; Tünde Troja | Zendy; Orlando Doehring | Zendy; Debra Carter | Zendy; John T. Monyak | Zendy; C. David Sjöström | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Once-Weekly Exenatide in Youth With Type 2 Diabetes

Author(s) -

William V. Tamborlane,

Raafat Bishai,

David H. Geller,

Naim Shehadeh,

Dalia AlAbdulrazzaq,

Evelina Mánica Vazquez,

Eva Karoly,

Tünde Troja,

Orlando Doehring,

Debra Carter,

John T. Monyak,

C. David Sjöström

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-2275

Subject(s) - exenatide , medicine , glycated hemoglobin , liraglutide , type 2 diabetes , placebo , metformin , diabetes mellitus , adverse effect , endocrinology , insulin , gastroenterology , alternative medicine , pathology

Approved treatments for type 2 diabetes in pediatric patients include metformin, liraglutide, and insulin. However, approximately one-half of the youth fail metformin monotherapy within 1 year, insulin therapy is associated with challenges, and liraglutide requires daily injections. Consequently, the efficacy and safety of once-weekly injections of exenatide for the treatment of youth with type 2 diabetes was evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research